Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed for an initial public offering (IPO) with the US Securities and Exchange Commission (SEC). The company aims to list on the Nasdaq under the ticker symbol POM, marking a significant step in its growth strategy.
Platform and Services
PomDoctor specializes in chronic disease management and medicine services, offering a one-stop medical service platform that connects patients, physicians, and drug suppliers. This integrated approach has positioned the company as a key player in the digital health sector, particularly for chronic conditions.
Financial Performance
During the first half of 2024, PomDoctor reported revenues of RMB 150 million (USD 20.7 million). Despite a net loss of RMB 66.75 million (USD 9.2 million), the company’s financial trajectory indicates strong potential for growth in the competitive online medical services market.
Investor Backing and Regulatory Approval
PomDoctor has secured backing from prominent investors including HongShan (formerly Sequoia Capital China), Jingdong Group (JD), and GTJA Investment across nine financing rounds from 2025 to 2021. The China Securities Regulatory Commission endorsed the company’s Nasdaq listing plans in January of this year.-Fineline Info & Tech
Leave a Reply